Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 7/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916049 | 1.00 | USP30 (0.52) | USP30USP2SMN1; SMN2PDE4BAAK1 | |
| SCHEMBL16936643 | 0.85 | USP30 (0.59) | USP30PDE4BNAMPT | |
| SCHEMBL23458809 | 0.84 | F11 (0.39) | USP30F2F11PRSS1PRSS2 | |
| SCHEMBL3695043 | 0.84 | F11 (0.39) | USP30F2F11PRSS1PRSS2 | |
| SCHEMBL30722164 | 0.84 | USP30 (0.42) | USP30USP2SMN1; SMN2PDE4BRORC | |
| SCHEMBL26987419 | 0.84 | USP30 (0.42) | USP30USP2SMN1; SMN2PDE4BRORC | |
| SCHEMBL180435 | 0.82 | USP30 (0.56) | USP30SMN1; SMN2PDE4BNAMPT | |
| SCHEMBL15775077 | 0.82 | USP30 (0.52) | USP30PDE4BAAK1RORCNAMPT | |
| SCHEMBL323889 | 0.82 | USP2 (0.46) | USP30USP2SMN1; SMN2PDE4BRORC | |
| SCHEMBL497161 | 0.82 | USP2 (0.46) | USP30USP2SMN1; SMN2PDE4BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421229-B2 | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | disclosed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4069693-A1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421229-B2 | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | TLR7, TLR9, TLR1 | USP30 4784/4885USP2 4615/4885SMN1; SMN2 4575/4885 |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | USP30 4799/4885USP2 4643/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.